A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results

Cornea

Volumn 30, Issue 11, 2011, Pages 1213-1218

  Enkvetchakul, Orapin ^a   Thanathanee, Onsiri ^a   Rangsin, Ram ^b   Lekhanont, Kaevalin ^c   Suwan Apichon, Olan ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

bevacizumab; primary; pterygium; treatment

Indexed keywords

ANTAZOLINE; BEVACIZUMAB; TETRYZOLINE;

ADULT; ARTICLE; BLURRED VISION; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; COREAL PTERYGIUM; DRUG EFFICACY; DRUG SAFETY; EPIPHORA; EYE DISCHARGE; EYE INFLAMMATION; EYE IRRITATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOPHOBIA; PRIORITY JOURNAL; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANTAZOLINE; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PTERYGIUM; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053621316     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31821c9b44     Document Type: Article

References (26)

1. Chui J, Di Girolamo N,Wakefield D, et al. The pathogenesis of pterygium: Current concepts and their therapeutic implications. Ocul Surf. 2008;6: 24-43. (Pubitemid 351902631)
2. Kato N, Shimmura S, Kawakita T, et al. Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci. 2007;48:1511-1517. (Pubitemid 351261333)
3. Lee JK, Song YS, Ha HS, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye (Lond). 2007;21:1186-1193. (Pubitemid 47382145)
4. Todani A, Melki SA. Pterygium: Current concepts in pathogenesis and treatment. Int Ophthalmol Clin. 2009;49:21-30.
5. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69: 925-927. (Pubitemid 47248101)
6. Mpyet C, Oko H. Results of intra-operative 0.5mg/ml mitomycin C with 20mg depo steroid in the treatment of primary pterygium. Cent Afr J Med. 2000;46:330-332.
7. Paris Fdos S, de Farias CC, Melo GB, et al. Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence. Cornea. 2008; 27:406-410. (Pubitemid 351591476)
8. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113:1102-1109. (Pubitemid 43947236)
9. Krag S, Ehlers N. Excimer laser treatment of pterygium. Acta Ophthalmol (Copenh). 1992;70:530-533.
10. Nakamura K, Bissen-Miyajima H, Shimmura S, et al. Clinical application of Er:YAG laser for the treatment of pterygium. Ophthalmic Surg Lasers. 2000;31:8-12. (Pubitemid 30053906)
11. Talu H, Tasindi E, Ciftci F, et al. Excimer laser phototherapeutic keratectomy for recurrent pterygium. J Cataract Refract Surg. 1998;24: 1326-1332. (Pubitemid 28473552)
12. Mauro J, Foster CS. Pterygia: Pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol. 2009;24:130-134.
13. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468-470.
14. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbalconjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
15. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
16. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
17. Fallah MR, Khosravi K, Hashemian MN, et al. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010;35:17-22.
18. Leippi S, Grehn F, Geerling G. Antiangiogenic therapy for pterygium recurrence [in German]. Ophthalmologe. 2009;106:413-419.
19. Bagri A, Kouros-Mehr H, Leong KG, et al. Use of anti-VEGF adjuvant therapy in cancer: Challenges and rationale. Trends Mol Med. 2010;16: 122-132.
20. Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: Implications for cancer therapy. Expert Opin Biol Ther. 2009; 9:1347-1356.
21. Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care. 2009;18:516-519.
22. Kang SY, Watnick RS. Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS. 2008;116:638-647.
23. Barrascout E, Medioni J, Scotte F, et al. Angiogenesis inhibition: Reviewof the activity of sorafenib, sunitinib and bevacizumab [in French]. Bull Cancer. 2010;97:29-43.
24. Maier M, Feucht N, Haas K, et al. Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV) [in German]. Klin Monbl Augenheilkd. 2008;225:818-824.
25. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina. 2009;29:319-324.
26. Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43:134-138.